LianRen Health Launches Standardized Healthcare Data Product 'LianYao' to Empower Pharma and Insurance Sectors

Healthcare data holds immense value, offering significant benefits to clinical diagnosis and treatment, hospital management, epidemic prevention and control, drug research and development, health insurance, and patients.

For instance, healthcare data can enhance the validity and accuracy of medical research, fostering the development of technologies and products that better align with clinical needs and offer greater cost-effectiveness; it can assist pharmaceutical companies in identifying the most suitable clinical scenarios for their drugs, thereby facilitating effective post-market development; furthermore, it can improve the precision of insurance services and strengthen the risk resilience of both the healthcare industry and patients.

The emergence of health and medical big data enterprises aims to unlock the potential value of big data by transforming “vast amounts of medical data” into actionable “medical big data.”

In 2022, LIANREN Digital Health, a health and medical big data enterprise with a state-owned central enterprise background, launchedStandardized Data Product “Lianyao”, providing customized medical big data services to pharmaceutical companies, insurers, investment institutions, and other participants in the healthcare industry.

“LianYao” is a deeply standardized data product developed by LIANREN Digital Health, leveraging government-authorized, large-scale regional health and medical big data. It provides pharmaceutical innovators and decision-makers with dynamically updated information aggregation and decision-support capabilities, initially launching with thematic reports on drugs and diseases.

Pharmaceutical Thematic Reports are in-depth analyses generated by aggregating real-world data from multiple hospitals, conducting statistical analysis across various dimensions such as market sales volumes (ranging from quarterly and semi-annual to three-to-five-year periods), actual drug utilization patterns, and characteristics of patient populations.

Disease-specific thematic reports are based on real-world data generated during patient diagnosis and treatment processes, presenting the current treatment status and baseline characteristics of patients in specific therapeutic areas across dimensions such as disease features, disease subtypes, laboratory tests, diagnostic examinations, departmental workflows, inter-hospital referrals, and disease burden.

“‘LianYao’ leverages the integration of regional health and medical big data to generate reports, transforming raw medical data into batch-processed, automated, and customized pharmaceutical reports. It also provides a simple and convenient query interface, effectively reducing the time and labor costs users incur in collecting, analyzing, and interpreting medical data.” LIANREN Digital HealthWang Fangyi, Deputy General Manager of the Pharmaceutical Business Divisionstated that “Lianyao” provides a pathway to gain insights into the development of pharmaceuticals and disease markets from a micro perspective, complementing the more common macro-level market analysis reports and offering content that is more closely aligned with clinical practice.

In July 2022, LIANREN Digital Health released its first standardized data product—the “LianYao” Special Report on Cardiovascular Drugs.

This report covers 53 drug categories in the fields of angina pectoris, hypertension, and/or hyperlipidemia. For each drug, it analyzes dozens of data dimensions, including sample characteristics (hospital tier and number of patients), demographic distribution (by gender and age group), healthcare utilization patterns (departmental distribution, concentration, and inter-departmental referrals), disease characteristics (distribution of primary and comorbid diagnoses), institutional sales performance, and disease burden. These insights are presented through visual charts to help users quickly grasp the development trends of relevant drugs and diseases.

According to the "Report on Cardiovascular Health and Diseases in China 2021," it is estimated that there are 330 million prevalent cases of cardiovascular disease (CVD) in China. The prevalence of CVD continues to rise, with two out of every five deaths attributed to cardiovascular causes. Cardiovascular disease has become a major public health concern affecting the population. Furthermore, cardiovascular medications have long accounted for a significant share of pharmaceutical sales in the Chinese market and are notably influenced by factors such as medical insurance policies.

This "Special Report on Cardiovascular Disease Medications" was generated by LIANREN Digital Health, leveraging its operational advantages in compliantly authorized regional health and medical big data centers. The report aggregates de-identified regional health and medical big data from more than ten hospitals in a prefecture-level city in Shandong Province over a continuous period of nearly five years. As a major economic and populous province on China’s eastern coast, Shandong is often regarded as a "microcosm of China" in terms of human geography, economic structure, and development layout. Therefore, this report holds considerable representativeness in both the volume and diversity of its data.

Liu Han, Head of Products, Pharmaceutical Business Unit, LIANREN Digital HealthIntroduction: Therapeutic areas characterized by large patient populations, high disease burden, a continuous influx of novel drugs, and significant unmet medical needs—such as cardiovascular diseases and malignant tumors—will be the primary focus for the subsequent product expansion of LIANREN Digital Health’s “Lianyao” platform. Currently, LIANREN Digital Health has produced relevant pharmaceutical and disease-specific thematic reports in fields including urological diseases, oncology, and macular degeneration.

Large-scale, high-quality data sources are a prerequisite for data development and application. Wang Fangyi stated that LIANREN Digital Health collaborates with provincial and municipal governments to aggregate, govern, and apply regional health and medical big data by leveraging existing regional platforms with established data foundations, such as comprehensive health information platforms and healthcare reform monitoring platforms. In addition to the National Health and Medical Big Data Center (North), LIANREN Digital Health has successively entered into collaborations with the governments of Chongqing, Ningbo, and Wenzhou to further synergize and advance explorations in the field of big data.

To maximize the value of big data in healthcare,LIANREN Digital Health, guided by its “Data as a Service (DaaS)” product philosophy, provides clinical trial data services to enterprises in the pharmaceutical sector with big data needs, including those in the pharmaceutical and medical device, insurance, and investment industries.Real-world insights services, precision marketing services, and technology services empower innovation in the pharmaceutical industry.

For pharmaceutical companies, patient recruitment has long been a bottleneck in clinical trials, as its pace largely determines the progress of clinical research. As drug therapies become increasingly precise, the pool of suitable candidates for each medication shrinks, making patient screening more challenging. Consequently, there is an urgent need for pharmaceutical companies to adopt measures that enable precise patient screening and matching. “LianYao” assists pharmaceutical companies in rapidly identifying target patient populations by providing data on patients’ disease conditions, departmental transfers, and patient journey information.

The annual and monthly dynamic changes in post-launch market sales and patient medication usage collected by LIANREN Digital Health can also help pharmaceutical companies obtain comprehensive and real-world assessments of patient medication patterns, evaluate research directions and investments for new drugs, and ultimately achieve patient benefits.

LIANREN Digital Health also supports insurance companies in benefit design and actuarial pricing, claims operations management, healthcare institution management, and market and sales expansion. It provides pharmaceutical and disease industry research reports to investment institutions, along with data on disease burden and other metrics to facilitate due diligence and risk assessment of startup enterprises, thereby empowering investors with industry data and insights.

While aggregating national health and medical big data resources, LIANREN Digital Health has simultaneously built corresponding capabilities in data processing, data mining, and the development of foundational data application platforms.LIANREN Digital Health’s independently developed “Renshu” big data platform has been upgraded to version 3.0.

“RenShu” is built on a “One Lake, Three Platforms” application architecture. By establishing a “Healthcare Big Data Lake” based on hybrid database architecture technologies, it constructs a data middle platform, a business-technology middle platform, and a development and application platform. Additionally, it sets up an operations and maintenance center and a security management center to support the exploration of operational models for healthcare big data, data de-identification and encryption, and the security assurance of data application processes.

Specifically, LIANREN Digital Health extracts, normalizes, cleanses, supplements, classifies, and centrally stores diverse raw medical data from thousands of various business systems across different medical institutions, disease control centers, civil affairs departments, and public security systems. It then constructs thematic databases tailored for pharmaceutical scenarios. Following several steps of data production and quality control processes, it generates sample datasets for drug reports and disease reports, which are stored in the LianYao Data Warehouse.

Standardize and statistically analyze datasets across various dimensions from the Lianren Health pharmaceutical data warehouse to generate data analysis reports on the market status of target drugs and diseases, which are then targeted to clients via offline reports and online interactive platforms.

In the process of data processing and application, LIANREN Digital Health has established unified data engineering standards by leveraging technologies such as natural language processing, thereby forming a knowledge support system for health and medical data operations. These efforts constitute foundational work for the large-scale application of regional health and medical data; only by solidifying this foundation can applications be steadily implemented and deployed.

From micro-level events to macro-level trends, only comprehensive coverage can provide a holistic perspective. Liu Han revealed,Drug-specific reports and disease-specific reports address users’ specific issues through micro-level data analysis. Moving forward, LIANREN Digital Health will expand its portfolio of thematic reports by incorporating topics such as big data-driven patient journeys and epidemiology, thereby enabling the monitoring of macro-level trends and meeting unmet market demands.

Overall, “LianYao” not only embodies LIANREN Digital Health’s corporate values of “Uniting Hearts and Strengths, Practicing Benevolence with Pragmatism,” but also serves as a bridge connecting healthcare big data with the needs of the pharmaceutical industry, aiming to achieve LIANREN Digital Health’s business objective of empowering the pharmaceutical sector through data, a new factor of production.

LIANREN Digital Health also aims to foster greater interaction with multiple stakeholders across the pharmaceutical, insurance, hospital, and government sectors, jointly building an open ecosystem for healthcare big data.